Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 28
Gene Symbol: ABO
ABO
0.080 Biomarker disease BEFREE Recently, ABO-ILKT has been recognized as a useful alternative therapy for end-stage kidney disease with ABO-incompatibility, and its outcome is comparable to that of ABO-CLKT. 31080772 2019
Entrez Id: 28
Gene Symbol: ABO
ABO
0.080 Biomarker disease BEFREE The accurate estimation of ABO antibody titers is of the utmost importance in organ transplants involving ABO incompatibility. 30125463 2019
Entrez Id: 28
Gene Symbol: ABO
ABO
0.080 Biomarker disease BEFREE Blood sample mixtures were divided into four groups: group M, cross-matched blood type mixing; group O, donor type O with other blood type mixing (A, B, or AB); group S, ABO type-specific uncross-matched blood mixing; and group I, ABO incompatibility mixing. 28846568 2018
Entrez Id: 28
Gene Symbol: ABO
ABO
0.080 Biomarker disease BEFREE The blood mixtures were divided into three groups: group M, cross-matched blood-type mixing (n = 20); group S, ABO type-specific uncross-matched blood (n = 20); and group I, ABO incompatibility (not ABO type-specific blood and not process cross-matched) mixing (n = 20). 29194343 2018
Entrez Id: 28
Gene Symbol: ABO
ABO
0.080 Biomarker disease BEFREE The cases were further subdivided into unexplained hyperbilirubinemia (n = 50), ABO(+) hyperbilirubinemia (n = 50), ABO(-) control (n = 50), and ABO(+) control (n = 50) groups on the basis of the presence or absence of DC(-) ABO incompatibility. 27842454 2017
Entrez Id: 28
Gene Symbol: ABO
ABO
0.080 GeneticVariation disease BEFREE The ABO incompatibility between the couples is likely to be a risk factor for early spontaneous abortions and also the heterozygote selection of ABO blood group genotypes. 21080445 2011
Entrez Id: 28
Gene Symbol: ABO
ABO
0.080 AlteredExpression disease BEFREE HIV vectors derived from cells expressing ABO antigens displayed sensitivity to fresh human serum analogous to ABO incompatibility, and ABO histo-blood group sugars were detected on the viral envelope protein, glycoprotein 120 (gp120). 15728127 2005
Entrez Id: 28
Gene Symbol: ABO
ABO
0.080 Biomarker disease BEFREE ABO incompatibility is associated with ABO immunization during pregnancy. 12021139 2002
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.030 Biomarker disease BEFREE Study of Gilbert's Syndrome-Associated UGT1A1 Polymorphism in Jaundiced Neonates of ABO Incompatibility Hemolysis Disease. 31087315 2019
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.030 GeneticVariation disease BEFREE UGT1A1 gene promoter polymorphism and G71R mutation are possible risk factors for Turkish neonates with DC(-) ABO incompatibility and unexplained hyperbilirubinemia. 27842454 2017
Entrez Id: 54658
Gene Symbol: UGT1A1
UGT1A1
0.030 GeneticVariation disease BEFREE The most common genetic variant was short heme oxygenase (HO)-1 promoter GT-allele (<24 repeats) (39.4 %), followed by GA at nt388 in hepatic solute carrier organic anion transporter 1B1 (SLCO1B1) (31.1 %), GA at nt211 in UDP-glucuronosyltransferase 1A1 (UGT1A1) (29.3 %), ABO incompatibility (16.2 %), alpha thalassemia (5.0 %), and G6PD deficiency (3.2 %). 27557546 2016
Entrez Id: 7124
Gene Symbol: TNF
TNF
0.020 Biomarker disease BEFREE Nor did neutralizing antibodies to tumor necrosis factor prevent MCP-1 production in ABO incompatibility. 8273123 1994
Entrez Id: 7124
Gene Symbol: TNF
TNF
0.020 Biomarker disease BEFREE We have constructed an in vitro whole blood model of HTR to examine whether TNF may be produced in red cell ABO incompatibility. 1911345 1991
Entrez Id: 952
Gene Symbol: CD38
CD38
0.010 Biomarker disease BEFREE The use of anti-CD38 therapy with daratumumab to target residual host plasma cells is safe and effective, and it can be considered in refractory recipients with PRCA after allo-HSCT secondary to ABO incompatibility. 31693245 2020
Entrez Id: 6531
Gene Symbol: SLC6A3
SLC6A3
0.010 Biomarker disease BEFREE Post-transplant positive DAT was associated with piperacillin-tazobactam use (P = 0·021) and minor ABO incompatibility (P = 0·0038). 31724190 2020
Entrez Id: 106480993
Gene Symbol: RN7SL263P
RN7SL263P
0.010 Biomarker disease BEFREE Major ABO incompatibility led to increased RBC transfusions. 31599972 2019
Entrez Id: 2539
Gene Symbol: G6PD
G6PD
0.010 Biomarker disease BEFREE The major causes of severe hyperbilirubinaemia were idiopathic (33.3%), sepsis (35.3%), ABO incompatibility (17.6%) and glucose-6-phosphate dehydrogenase (G6PD) deficiency (11.8%). 29935542 2018
Entrez Id: 54578
Gene Symbol: UGT1A6
UGT1A6
0.010 GeneticVariation disease BEFREE The most common genetic variant was short heme oxygenase (HO)-1 promoter GT-allele (<24 repeats) (39.4 %), followed by GA at nt388 in hepatic solute carrier organic anion transporter 1B1 (SLCO1B1) (31.1 %), GA at nt211 in UDP-glucuronosyltransferase 1A1 (UGT1A1) (29.3 %), ABO incompatibility (16.2 %), alpha thalassemia (5.0 %), and G6PD deficiency (3.2 %). 27557546 2016
Entrez Id: 54576
Gene Symbol: UGT1A8
UGT1A8
0.010 GeneticVariation disease BEFREE The most common genetic variant was short heme oxygenase (HO)-1 promoter GT-allele (<24 repeats) (39.4 %), followed by GA at nt388 in hepatic solute carrier organic anion transporter 1B1 (SLCO1B1) (31.1 %), GA at nt211 in UDP-glucuronosyltransferase 1A1 (UGT1A1) (29.3 %), ABO incompatibility (16.2 %), alpha thalassemia (5.0 %), and G6PD deficiency (3.2 %). 27557546 2016
Entrez Id: 54657
Gene Symbol: UGT1A4
UGT1A4
0.010 GeneticVariation disease BEFREE The most common genetic variant was short heme oxygenase (HO)-1 promoter GT-allele (<24 repeats) (39.4 %), followed by GA at nt388 in hepatic solute carrier organic anion transporter 1B1 (SLCO1B1) (31.1 %), GA at nt211 in UDP-glucuronosyltransferase 1A1 (UGT1A1) (29.3 %), ABO incompatibility (16.2 %), alpha thalassemia (5.0 %), and G6PD deficiency (3.2 %). 27557546 2016
Entrez Id: 54575
Gene Symbol: UGT1A10
UGT1A10
0.010 GeneticVariation disease BEFREE The most common genetic variant was short heme oxygenase (HO)-1 promoter GT-allele (<24 repeats) (39.4 %), followed by GA at nt388 in hepatic solute carrier organic anion transporter 1B1 (SLCO1B1) (31.1 %), GA at nt211 in UDP-glucuronosyltransferase 1A1 (UGT1A1) (29.3 %), ABO incompatibility (16.2 %), alpha thalassemia (5.0 %), and G6PD deficiency (3.2 %). 27557546 2016
Entrez Id: 10599
Gene Symbol: SLCO1B1
SLCO1B1
0.010 GeneticVariation disease BEFREE The most common genetic variant was short heme oxygenase (HO)-1 promoter GT-allele (<24 repeats) (39.4 %), followed by GA at nt388 in hepatic solute carrier organic anion transporter 1B1 (SLCO1B1) (31.1 %), GA at nt211 in UDP-glucuronosyltransferase 1A1 (UGT1A1) (29.3 %), ABO incompatibility (16.2 %), alpha thalassemia (5.0 %), and G6PD deficiency (3.2 %). 27557546 2016
Entrez Id: 54577
Gene Symbol: UGT1A7
UGT1A7
0.010 GeneticVariation disease BEFREE The most common genetic variant was short heme oxygenase (HO)-1 promoter GT-allele (<24 repeats) (39.4 %), followed by GA at nt388 in hepatic solute carrier organic anion transporter 1B1 (SLCO1B1) (31.1 %), GA at nt211 in UDP-glucuronosyltransferase 1A1 (UGT1A1) (29.3 %), ABO incompatibility (16.2 %), alpha thalassemia (5.0 %), and G6PD deficiency (3.2 %). 27557546 2016
Entrez Id: 6347
Gene Symbol: CCL2
CCL2
0.010 Biomarker disease BEFREE Nor did neutralizing antibodies to tumor necrosis factor prevent MCP-1 production in ABO incompatibility. 8273123 1994